Summary
CVS Health Corporation reported a significant decline in net income attributable to CVS Health for the third quarter and first nine months of 2024 compared to the same periods in 2023. This was largely driven by substantial restructuring charges of $1.2 billion in Q3 2024, a substantial increase in health care costs, and the recording of significant premium deficiency reserves, particularly within the Health Care Benefits segment. Total revenues saw a modest increase year-over-year, primarily due to growth in premiums and services, but this was outpaced by rising operating costs and health care expenses. Despite the reported net income decline, the company highlighted positive revenue growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, elevated utilization, especially in Medicare Advantage programs, along with medical cost pressures in the Medicaid business, continue to strain the Health Care Benefits segment, leading to substantial premium deficiency reserves. The company is also navigating ongoing litigation, including significant opioid settlements. Management has initiated an enterprise-wide restructuring plan to improve efficiency and reduce costs, which contributed to the substantial charges in the current quarter.
Financial Highlights
54 data points| Revenue | $95.43B |
| Cost of Revenue | $52.95B |
| Gross Profit | $42.48B |
| Operating Expenses | $94.60B |
| Operating Income | $832.00M |
| Net Income | $87.00M |
| EPS (Basic) | $0.07 |
| EPS (Diluted) | $0.07 |
| Shares Outstanding (Basic) | 1.26B |
| Shares Outstanding (Diluted) | 1.26B |
Key Highlights
- 1Total revenues increased by 6.3% to $95.4 billion for the three months ended September 30, 2024, and by 4.2% to $275.1 billion for the nine months ended September 30, 2024.
- 2Net income attributable to CVS Health significantly decreased by 96.2% to $87 million in Q3 2024 and by 52.8% to $2.97 billion for the nine months ended September 30, 2024, compared to the prior year periods.
- 3The company recorded substantial restructuring charges of $1.2 billion in Q3 2024, primarily related to store impairments, corporate workforce optimization, and other asset impairments.
- 4Health care costs increased significantly by 39.2% in Q3 2024 and 34.3% for the nine-month period, largely due to increased utilization and the recording of approximately $1.1 billion in premium deficiency reserves.
- 5The Health Care Benefits segment experienced a notable decline in operating income, reporting an adjusted operating loss of $924 million in Q3 2024 compared to an adjusted operating income of $1.5 billion in the prior year, driven by increased utilization and premium deficiency reserves.
- 6The company repurchased approximately $3.0 billion of common stock in the first nine months of 2024.
- 7CVS Health is facing ongoing litigation, including opioid settlements, with a maximum payable amount of approximately $4.3 billion related to opioid remediation.